WO2004080373A3 - Diagnostics and therapeutics for diseases associated with g-protein coupled proteinase activated receptor 2 (par2) - Google Patents

Diagnostics and therapeutics for diseases associated with g-protein coupled proteinase activated receptor 2 (par2) Download PDF

Info

Publication number
WO2004080373A3
WO2004080373A3 PCT/EP2004/001896 EP2004001896W WO2004080373A3 WO 2004080373 A3 WO2004080373 A3 WO 2004080373A3 EP 2004001896 W EP2004001896 W EP 2004001896W WO 2004080373 A3 WO2004080373 A3 WO 2004080373A3
Authority
WO
WIPO (PCT)
Prior art keywords
par2
therapeutics
diagnostics
diseases
diseases associated
Prior art date
Application number
PCT/EP2004/001896
Other languages
French (fr)
Other versions
WO2004080373A2 (en
Inventor
Stefan Golz
Ulf Brueggemeier
Holger Summer
Original Assignee
Bayer Healthcare Ag
Stefan Golz
Ulf Brueggemeier
Holger Summer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag, Stefan Golz, Ulf Brueggemeier, Holger Summer filed Critical Bayer Healthcare Ag
Priority to EP04714741A priority Critical patent/EP1604207A2/en
Priority to US10/548,421 priority patent/US20070053911A1/en
Publication of WO2004080373A2 publication Critical patent/WO2004080373A2/en
Publication of WO2004080373A3 publication Critical patent/WO2004080373A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders

Abstract

The invention provides a human PAR2 which is associated with the cardiovascular disorders, gastrointestinal and liver diseases, neurological disorders, urological disorders, hematological diseases and respiratory diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular disorders, gastrointestinal and liver diseases, neurological disorders, urological disorders, hematological diseases and respiratory diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of PAR2 as well as pharmaceutical compositions comprising such compounds.
PCT/EP2004/001896 2003-03-11 2004-02-26 Diagnostics and therapeutics for diseases associated with g-protein coupled proteinase activated receptor 2 (par2) WO2004080373A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP04714741A EP1604207A2 (en) 2003-03-11 2004-02-26 Diagnostics and therapeutics for diseases associated with g-protein coupled proteinase activated receptor 2 (par2)
US10/548,421 US20070053911A1 (en) 2003-03-11 2004-02-26 Diagnostics and therapeutics for diseases associated with g-protein coupled proteinase activated receptor 2 (par2)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03004980 2003-03-11
EP03004980.3 2003-03-11

Publications (2)

Publication Number Publication Date
WO2004080373A2 WO2004080373A2 (en) 2004-09-23
WO2004080373A3 true WO2004080373A3 (en) 2005-06-23

Family

ID=32981726

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/001896 WO2004080373A2 (en) 2003-03-11 2004-02-26 Diagnostics and therapeutics for diseases associated with g-protein coupled proteinase activated receptor 2 (par2)

Country Status (3)

Country Link
US (1) US20070053911A1 (en)
EP (1) EP1604207A2 (en)
WO (1) WO2004080373A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006016450A1 (en) * 2004-08-11 2006-02-16 Kowa Company, Ltd. Method of preventing and treating brain infarction
US20080318960A1 (en) * 2005-05-26 2008-12-25 Ethan Burstein PAR2-modulating compounds and their use
US7888482B2 (en) 2006-02-10 2011-02-15 Amgen Inc. Antibodies that bind PAR-2
CL2008001887A1 (en) 2007-06-29 2008-10-03 Amgen Inc PROTEINS OF UNION TO ANTIGEN THAT JOIN THE RECEPTOR ACTIVATED BY PROTEASES 2 (PAR-2); NUCLEIC ACID THAT CODES THEM; VECTOR AND GUEST CELL; METHOD OF PRODUCTION; AND COMPOSITION THAT UNDERSTANDS THEM.
WO2012077105A2 (en) * 2010-12-07 2012-06-14 Bio-Marcare Technologies Ltd. Biomarkers for detecting a cancerous state in a subject
WO2012090207A2 (en) * 2010-12-30 2012-07-05 Hadasit Medical Research Services & Development Limited Par1 and par2 c-tail peptides and peptide mimetics
US20160000791A1 (en) 2014-07-07 2016-01-07 Mayo Foundation For Medical Education And Research Par1 modulation to alter myelination
KR20190129925A (en) * 2017-03-16 2019-11-20 메디뮨 리미티드 Anti-PAR2 Antibodies and Their Uses
EP4090372A4 (en) * 2020-01-14 2023-10-18 Mayo Foundation for Medical Education and Research Targeting par1 and par2 to regulate lipid and cholesterol abundance

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CICALA C ET AL: "Protective effect of a PAR2-activating peptide on histamine-induced bronchoconstriction in guinea-pig", BRITISH JOURNAL OF PHARMACOLOGY, vol. 132, no. 6, March 2001 (2001-03-01), pages 1229 - 1234, XP002294684, ISSN: 0007-1188 *
COMPTON S J ET AL: "A polymorphic protease activated receptor 2 (PAR2) displaying reduced sensitivity toi trypsin and differential responses to par agonists", 8 March 2001, FASEB JOURNAL (FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL BIOLOGY), BETHESDA, US, PAGE(S) A931,ABSTRACT7207, ISSN: 0892-6638, XP002958514 *
KAWABATA A ET AL: "EVALUATION OF PROTEINASE-ACTIVATED RECEPTOR-1 (PAR1) AGONISTS AND ANTAGONISTS USING A CULTURED CELL RECEPTOR DESENSITIZATION ASSAY: ACTIVATION OF PAR2 BY PAR1-TARGETED LIGANDS", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, AMERICAN SOCIETY FOR PHARMACOLOGY AND, US, vol. 288, no. 1, January 1999 (1999-01-01), pages 358 - 370, XP000946514, ISSN: 0022-3565 *
SCHMIDLIN FABIEN ET AL: "Expression and function of proteinase-activated receptor 2 in human bronchial smooth muscle", 1 October 2001, AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, VOL. 164, NR. 7, PAGE(S) 1276-1281, ISSN: 1073-449X, XP002294685 *

Also Published As

Publication number Publication date
EP1604207A2 (en) 2005-12-14
US20070053911A1 (en) 2007-03-08
WO2004080373A2 (en) 2004-09-23

Similar Documents

Publication Publication Date Title
WO2005093092A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 44 (gpr44)
WO2004080373A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled proteinase activated receptor 2 (par2)
WO2005095973A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 54 (gpr54)
WO2005040828A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 49 (gpr49)
WO2005095972A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor etb (etb)
WO2005050225A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 84 (gpr84)
WO2004082568A3 (en) Diagnostics and therapeutics for diseases associated with complement component 5a receptor (c5ar)
WO2005093091A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 26 (gpr26)
WO2004104574A3 (en) Diagnostics and therapeutics for diseases associated with c-c chemokine receptor type 7 (ccr7)
WO2005040825A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 20 (gpr20)
WO2004082571A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 86 (gpr86)
WO2005059546A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 35 (gpr35)
WO2005040211A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 1 (gpr1)
WO2005108998A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor beta-3 adreno (adrb3)
WO2004082572A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 87 (gpr87)
WO2004104577A3 (en) Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine (serotonin) receptor 4 (5-ht4)
WO2005003762A3 (en) Diagnostics and therapeutics for diseases associated with sensory neuron-specific g protein-coupled receptor 2 (snsr2)
WO2004099783A3 (en) Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor ltb4 (ltb4)
WO2004099248A3 (en) Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor agtr2 (agtr2)
WO2005040824A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 24 (gpr24)
WO2004082566A3 (en) Diagnostics and therapeutics for diseases associated with complement component 3a receptor 1 (c3ar1)
WO2005040790A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 75 (gpr75)
WO2004086034A3 (en) Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor adenosine a3(adora3)
WO2004097422A3 (en) Diagnostics and therapeutics for diseases associated with calcitonin receptor (calcr)
WO2004097405A3 (en) Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor h7tba62 (h7tba62)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004714741

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004714741

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007053911

Country of ref document: US

Ref document number: 10548421

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10548421

Country of ref document: US